NovoCure EPS misses by $0.09, beats on revenue

S&P ASX All Technology

US Dollar vs AUD

Level up your trading with our powerful tools and real-time insights all in one place.

Get Started

NovoCure EPS misses by $0.09, beats on revenue

To read the full story on Seeking Alpha, click here.

NovoCure (NASDAQ:NVCR)
Historical Stock Chart
From Apr 2024 to May 2024

Click Here for more NovoCure Charts.

NovoCure (NASDAQ:NVCR)
Historical Stock Chart
From May 2023 to May 2024

Click Here for more NovoCure Charts.

NovoCure Ltd News

Novocure Secures New $400 Million Multi-Tranche Non-Dilutive Debt Financing from Pharmakon
Thursday 2 May 2024 (3 days ago) • Business Wire

Novocure Reports First Quarter 2024 Financial Results
Thursday 2 May 2024 (3 days ago) • Business Wire

Results of Novocure’s METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024
Thursday 25 April 2024 (2 weeks ago) • Business Wire

Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024
Friday 5 April 2024 (1 month ago) • Business Wire

Novocure to Report First Quarter 2024 Financial Results
Monday 1 April 2024 (1 month ago) • Business Wire

METIS第3相臨床試験で主要評価項目を達成、非小細胞肺がんからの脳転移患者における頭蓋内進行までの期間を統計学的に有意に延長
Friday 29 March 2024 (1 month ago) • Business Wire

Klinische Phase-3-Studie METIS erreicht primären Endpunkt und zeigt eine statistisch signifikante Verlängerung der Zeit bis zur intrakraniellen Progression bei Patient:innen mit Hirnmetastasen von nicht-kleinzelligem Lungenkrebs
Friday 29 March 2024 (1 month ago) • Business Wire

L’essai clinique de phase 3 METIS a atteint son critère principal, démontrant un allongement statistiquement significatif du délai médian jusqu’à la progression intracrânienne chez les patients porteurs de métastases cérébrales consécutives..
Friday 29 March 2024 (1 month ago) • Business Wire

METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer
Wednesday 27 March 2024 (1 month ago) • Business Wire

INNOVATE-3 Late Breaking Abstract Selected as a Best Oral Presentation at ESGO
Monday 11 March 2024 (2 months ago) • Business Wire

Form 4 - Statement of changes in beneficial ownership of securities
Wednesday 6 March 2024 (2 months ago) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Tuesday 5 March 2024 (2 months ago) • Edgar (US Regulatory)

More NovoCure Ltd News Articles

Commonwealth Bank Of Aus...

Verizon Communications

Australian SE All Ordina...

AUD vs US Dollar

Woodside Petroleum

Westpac Banking

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions